Werewolf Therapeutics, Inc. (NASDAQ:HOWL – Get Free Report)’s stock price crossed below its 50-day moving average during trading on Thursday. The stock has a 50-day moving average of $0.99 and traded as low as $0.95. Werewolf Therapeutics shares last traded at $0.9857, with a volume of 560,895 shares.
Wall Street Analysts Forecast Growth
A number of equities research analysts have commented on the company. Zacks Research downgraded Werewolf Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Tuesday, November 3rd. Wall Street Zen raised shares of Werewolf Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, August 22nd. Finally, Weiss Ratings downgraded shares of Werewolf Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a report on Friday. One analyst has rated the stock with a Buy rating, four have given a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average target price of $2.50.
View Our Latest Report on HOWL
Werewolf Therapeutics Stock Performance
The firm has a market cap of $45.44 million, a price-to-earnings ratio of -1.56 and a beta of 0.55. The business has a fifty day moving average of $0.99 and a two-hundred day moving average of $0.71.
Werewolf Therapeutics (NASDAQ:HOWL – Get Free Report) last issued its quarterly earnings data on Friday, November 13th. The company reported ($0.20) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.22) by $0.02. On average, equities research analysts forecast that Werewolf Therapeutics, Inc. will post -0.89 earnings per share for the current year.
Institutional Inflows and Outflows
Hedge funds and other institutional investors have recently made changes to their positions in the company. Covestor Ltd acquired a new stake in Werewolf Therapeutics in the 3rd quarter valued at about $124,000. Bank of America Corp DE acquired a new position in Werewolf Therapeutics during the second quarter worth about $112,000. Virtu Financial LLC lifted its holdings in shares of Werewolf Therapeutics by 99.6% in the third quarter. Virtu Financial LLC now owns 90,749 shares of the company’s stock valued at $84,000 after purchasing an additional 45,282 shares in the last quarter. Vontobel Holding Ltd. purchased a new stake in shares of Werewolf Therapeutics in the third quarter valued at about $55,000. Finally, StoneX Group Inc. grew its position in shares of Werewolf Therapeutics by 174.3% in the third quarter. StoneX Group Inc. now owns 54,856 shares of the company’s stock valued at $51,000 after purchasing an additional 34,856 shares during the last quarter. Institutional investors and hedge funds own 64.84% of the company’s stock.
Werewolf Therapeutics Company Profile
Werewolf Therapeutics, Inc. is a clinical-stage biotechnology company developing medicines for cancer. Its research focuses on cytokines, immune-signaling proteins that can stimulate the body’s immune response against tumors. The company’s INDUKINE platform is designed to keep cytokine therapies inactive until they reach the tumor environment, with the goal of limiting effects on healthy tissue. Its investigational programs include WTX-124, based on interleukin-2, and WTX-330, based on interleukin-12.
Further Reading
- Five stocks we like better than Werewolf Therapeutics
- ZIM Just Posted Huge Profits, But Its $35 Buyout Is Still in Limbo
- Owens Corning’s Stock Slump May Have a Silver Lining for Dividend Investors
- The Patchpocalypse Could Be a Big Opportunity for These 2 Cybersecurity Stocks
- Anthropic’s Record IPO Could Ease a Major Concern for Broadcom Investors
Receive News & Ratings for Werewolf Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Werewolf Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
